Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07063316

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The objectives of the study are: 1. To compare the risk and timing of anemia onset between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor users and non-users in patients with chronic kidney disease (CKD) from the index date to first event occurrence or the end date of each individual's follow-up. 2. To compare the following outcomes from the index date to 731 days (24 months) or the end date of each individual's follow-up: A) Longitudinal changes in laboratory values between SGLT2 inhibitor users and non-users in patients with CKD. B) Prescription patterns and treatment regimens for anemia between SGLT2 inhibitor users and non-users in patients with CKD, including analysis of medication types, dosing strategies, and duration of treatments. C) Anemia-related healthcare costs between SGLT2 inhibitor users and non-users.

Official title: Effect of SGLT2 Inhibitors on Renal Anemia and Its Management in Patients With CKD in Japan

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

15000

Start Date

2025-07-23

Completion Date

2026-09-30

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

DRUG

SGLT2 inhibitor

SGLT2 inhibitor

Locations (1)

Nippon Boehringer Ingelheim Co ., Ltd.

Tokyo, Japan